How Hyperbaric Oxygen Therapy May Address Hematuria and Chronic Bladder Injury After Prostate Radiation
Radiation therapy is an established treatment for localized, locally advanced, recurrent, and postoperative prostate cancer. External beam radiation therapy, brachytherapy, and salvage radiation after prostatectomy can provide effective cancer control, but the bladder neck, bladder base, prostatic urethra, and surrounding pelvic tissues may receive radiation during treatment.
Some urinary effects occur during radiation and improve after treatment ends. Radiation cystitis is a delayed complication that may appear months or years later. Patients may develop urinary frequency, urgency, burning, pelvic discomfort, reduced bladder capacity, or blood in the urine. In severe cases, hematuria can produce clots, urinary retention, anemia, transfusion requirements, emergency visits, and repeated urologic procedures.
Hyperbaric oxygen therapy, or HBOT, may be considered when symptoms are caused by delayed radiation injury and persist despite appropriate urologic care. HBOT does not treat prostate cancer itself. Its purpose is to improve the oxygenation and vascular health of previously irradiated bladder tissue.
Why Radiation Cystitis Can Develop Years After Prostate Cancer Treatment
Radiation can damage the endothelial cells that line small blood vessels within the bladder wall. Over time, affected vessels may narrow, thrombose, or disappear. This progressive loss of microvascular supply leaves the tissue chronically hypoxic, less cellular, and less capable of normal repair.
The bladder lining may become thin and fragile. Abnormal telangiectatic vessels can form within the irradiated mucosa and rupture as the bladder fills, empties, or is exposed to minor mechanical stress. Fibrosis may also reduce bladder elasticity and contribute to urgency, frequent urination, pain during filling, and decreased functional capacity.
This delayed process differs from the temporary inflammation that may occur during prostate radiation. Acute urinary symptoms often result from mucosal irritation and swelling. Chronic radiation cystitis reflects a longer-term pattern of vascular injury, hypoxia, fibrosis, and abnormal tissue remodeling.
The delayed timing can be unsettling for patients who completed prostate cancer treatment years earlier. New hematuria may immediately raise concerns about cancer recurrence. Those concerns deserve a complete evaluation rather than an assumption that radiation is the cause. (PubMed Central (PMC))
Hematuria After Prostate Radiation Requires a Urologic Workup
Blood in the urine after prostate cancer treatment should not automatically be attributed to radiation cystitis. Other conditions may produce similar symptoms, including:
- Bladder or upper urinary tract cancer
- Recurrent or persistent prostate cancer
- Urinary tract infection
- Kidney or bladder stones
- Benign prostatic or prostatic urethral bleeding
- Urethral stricture or bladder-neck contracture
- Renal disease
- Recent catheterization or instrumentation
- Anticoagulant or antiplatelet therapy
The evaluation commonly begins with a detailed history, physical examination, urinalysis, urine culture, blood counts, renal function testing, and review of medications. The clinician should determine the severity and duration of bleeding, whether clots are present, whether the patient can empty the bladder, and whether anemia or hemodynamic compromise has developed.
Cystoscopy allows the urologist to inspect the bladder lining, identify characteristic telangiectasia or ulceration, remove clots, treat focal bleeding, and evaluate suspicious lesions. Upper urinary tract imaging may also be needed, particularly in patients with gross hematuria or other risk factors for urinary tract malignancy. Suspicious bladder lesions may require biopsy, although tissue sampling should be planned carefully because irradiated tissue may heal poorly. (PubMed Central (PMC))
Prostate cancer surveillance should continue according to the patient’s oncologic plan. The prostate-specific antigen trend, original cancer characteristics, treatment history, imaging, and clinical findings help determine whether recurrent disease requires further investigation.
Anticoagulation Can Increase the Severity of Bleeding
Many prostate cancer survivors are older adults with atrial fibrillation, coronary artery disease, previous stroke, venous thromboembolism, or other conditions requiring anticoagulant or antiplatelet therapy.
These medications do not necessarily cause the underlying radiation injury, but they can increase the frequency or severity of bleeding from fragile bladder vessels. Medication review is therefore an important part of the evaluation.
Anticoagulation should not be stopped without direction from the prescribing clinician. The risk of continued hematuria must be balanced against the risk of stroke, myocardial infarction, recurrent thrombosis, or another serious cardiovascular event.
When bleeding is clinically significant, urology, cardiology, hematology, primary care, and the prescribing specialist may need to coordinate:
- Whether medication interruption is medically acceptable
- How long an interruption can safely continue
- Whether dose adjustment is appropriate
- Whether an alternative medication is reasonable
- When treatment should be restarted
- Whether correction of another bleeding risk factor is possible
HBOT may improve the condition of the irradiated bladder tissue, but medication management remains individualized and should continue throughout the treatment course.
How HBOT May Help the Radiation-Damaged Bladder
During HBOT, the patient breathes medical oxygen while exposed to increased atmospheric pressure inside a hyperbaric chamber. The increased pressure raises arterial oxygen tension and substantially increases the amount of oxygen dissolved directly in plasma.
This oxygen-rich plasma can reach functioning vessels at the margins of the radiation field and create a stronger diffusion gradient into hypoxic bladder tissue.
Repeated hyperbaric exposures may support:
- Angiogenic signaling and formation of new capillary networks
- Increased tissue oxygenation between treatments
- Fibroblast activity and collagen remodeling
- Repair of the bladder’s epithelial lining
- Improved integrity of damaged blood vessels
- Modulation of chronic inflammatory activity
- Greater resistance to recurrent tissue breakdown
HBOT is therefore different from a procedure intended to cauterize a single bleeding vessel. Cystoscopic fulguration may stop an identifiable bleeding point, while HBOT is intended to improve the broader tissue environment responsible for recurrent bleeding.
This restorative process takes time. Some patients notice reduced hematuria during treatment. Others improve gradually in the weeks or months following the treatment course as vascular remodeling continues. (AUANews)
Severe Hematuria Must Be Stabilized First
HBOT is not an emergency method of removing clots or immediately controlling major blood loss.
A patient with heavy bleeding, urinary obstruction, symptomatic anemia, or hemodynamic instability may require:
- Placement of a large-bore urinary catheter
- Manual clot evacuation
- Continuous bladder irrigation
- Intravenous fluids
- Blood transfusion or iron replacement
- Correction of clinically significant coagulopathy
- Cystoscopic clot evacuation
- Fulguration or coagulation of active bleeding sites
- Hospital admission and close monitoring
Persistent life-threatening bleeding may require intravesical agents, selective arterial embolization, urinary diversion, or surgery. The selected treatment depends on the severity of bleeding, bladder condition, renal function, prior procedures, and the patient’s overall health.
HBOT may begin after the patient is stable enough to attend repeated chamber treatments. It can be incorporated relatively early when bleeding continues or recurs after appropriate cystoscopic management, rather than being reserved only for patients who have exhausted every invasive option. (PubMed Central (PMC))
Which Prostate Cancer Patients May Be Candidates for HBOT?
A hyperbaric evaluation may be appropriate when a patient has documented pelvic radiation exposure and persistent symptoms consistent with delayed bladder radiation injury.
Potential candidates include patients with:
- Recurrent visible hematuria attributed to radiation cystitis
- Bleeding that returns after cystoscopic fulguration
- Diffuse bladder telangiectasia that is difficult to treat focally
- Radiation-associated bladder ulceration
- Repeated clot-retention episodes
- Iron-deficiency anemia or transfusion requirements
- Persistent urgency, frequency, dysuria, or pelvic discomfort
- A desire to preserve bladder function and avoid more destructive treatment
- Concurrent radiation injury involving other pelvic tissues
The hyperbaric physician should review the prostate cancer treatment history, including radiation modality, treatment field, dose when available, date of completion, previous pelvic surgery, and any subsequent cancer therapy.
The evaluation should also address pulmonary and cardiovascular history, ear-pressure equalization, glucose management, seizure risk, implanted devices, current medications, and the patient’s ability to complete a prolonged treatment schedule.
HBOT is less likely to correct symptoms caused primarily by a fixed structural problem, such as a severe urethral stricture, bladder-neck contracture, established fistula, large bladder stone, active tumor, or severely contracted bladder. These conditions may require separate urologic or surgical management.
Prostatectomy and Salvage Radiation Can Create Additional Complexity
Some patients receive radiation after radical prostatectomy because of adverse pathologic findings, a persistently detectable PSA, or biochemical recurrence. These patients may have urinary incontinence, bladder-neck scarring, altered pelvic anatomy, or previous surgical complications before radiation begins.
When hematuria or lower urinary tract symptoms later develop, several treatment-related factors may overlap:
- Radiation cystitis
- Bladder-neck contracture
- Urethral stricture
- Surgical clip or foreign-body complications
- Stress urinary incontinence
- Recurrent malignancy
- Infection or instrumentation-related trauma
A careful urologic evaluation is needed to determine which condition is responsible for each symptom. HBOT may address delayed radiation tissue injury, but it will not mechanically open a stricture or correct sphincter dysfunction.
This distinction helps establish realistic treatment goals. Reduced bleeding may be achievable even when preexisting incontinence or obstruction requires separate treatment.
What an HBOT Course May Involve
Treatment is prescribed by a hyperbaric physician based on the bladder injury, medical history, previous interventions, treatment tolerance, and clinical response.
Many radiation cystitis protocols involve:
- Treatment five days per week
- Approximately 30 to 40 initial sessions
- Pressure between about 2.0 and 2.5 atmospheres absolute
- Approximately 80 to 90 minutes of oxygen breathing at treatment pressure
- Air breaks when included in the prescribed protocol
The RICH-ART randomized trial used 30 to 40 treatments at approximately 2.4 to 2.5 atmospheres absolute, with 80 to 90 minutes of oxygen exposure per session. (PubMed)
A typical treatment visit includes a clinical assessment, removal of prohibited items, gradual chamber compression, oxygen exposure at the prescribed pressure, controlled decompression, and post-treatment assessment.
Patients may be treated in a monoplace or multiplace chamber. The clinical dose, safety systems, staff competency, and ability to monitor the patient are more important than the chamber configuration.
Blood Glucose and Cardiovascular Health Require Attention
Prostate cancer survivors frequently have diabetes, hypertension, coronary disease, arrhythmias, or heart failure. These conditions do not automatically prevent HBOT, but they influence treatment planning.
Patients with diabetes commonly require glucose testing before treatment. Meal timing, insulin administration, oral medications, and recent glucose trends should be reviewed because hypoglycemic symptoms can be difficult to evaluate inside a pressurized chamber.
Hyperbaric oxygen can increase systemic vascular resistance and reduce heart rate and cardiac output. Patients with unstable or decompensated heart failure should be medically optimized before treatment. New dyspnea, edema, chest pain, or changes in exercise tolerance should be reported promptly.
The goal of screening is not simply to identify whether the patient can enter the chamber. It is to create a treatment plan that accounts for the individual’s broader cardiovascular, pulmonary, metabolic, and oncologic health.
Measuring Whether HBOT Is Working
Visible hematuria is an important outcome, but it is not the only measure of treatment benefit.
Clinical progress may include:
- Fewer bleeding episodes
- Reduced volume of blood or clot passage
- Fewer emergency visits
- Reduced need for irrigation or catheterization
- Stabilization of hemoglobin
- Reduced transfusion or iron-replacement requirements
- Improved urinary frequency or urgency
- Reduced dysuria or bladder discomfort
- Better sleep and daily function
- Reduced need for additional invasive procedures
Patient-reported outcomes are particularly valuable because chronic radiation cystitis can affect several aspects of urinary function simultaneously. A patient may consider treatment worthwhile because urgency improves enough to permit travel or uninterrupted sleep, even when occasional mild hematuria persists.
The Expanded Prostate Cancer Index Composite, or EPIC, has been used in radiation cystitis research to measure urinary symptoms and their effect on quality of life. The RICH-ART trial demonstrated improvement in patient-reported urinary outcomes after HBOT compared with standard care. (AME Medical Journal)
What the Evidence Shows
The evidence supporting HBOT for chronic radiation cystitis includes cohort studies, systematic reviews, and a multicenter randomized phase 2 to 3 trial.
A 2024 systematic review and meta-analysis involving patients with radiation-induced hemorrhagic cystitis found overall symptom improvement in approximately 90 percent of treated patients. Complete remission of hematuria occurred in a pooled 55 percent. The included studies varied in severity, treatment protocol, follow-up, and definitions of success, so these figures should not be presented as a guaranteed individual outcome. (PubMed Central (PMC))
Studies focused specifically on men treated for prostate cancer have reported durable improvement following HBOT, although results vary according to baseline bleeding severity and other clinical factors. One prostate cancer cohort found that the initial grade of hematuria was associated with the likelihood of resolution, information that may be useful during shared decision-making. (PubMed Central (PMC))
The 2025 five-year follow-up of the RICH-ART trial provides important long-term evidence. Among 70 patients included in the follow-up analysis, 48, or 68.6 percent, met the study’s responder definition after HBOT. Symptom improvements remained clinically meaningful over five years in the responder group, although some patients received an additional HBOT course after symptoms recurred. (PubMed)
These findings support HBOT as a durable treatment option for selected patients, but not every patient responds completely. Severe structural bladder damage, continued anticoagulation, recurrent malignancy, extensive ulceration, delayed referral, and other health conditions may affect the outcome.
Risks and Contraindications
HBOT is generally well tolerated when it is delivered in a medically supervised facility, but it has recognized risks.
Potential adverse effects include:
- Middle-ear or sinus barotrauma
- Temporary myopic vision changes
- Claustrophobia or confinement anxiety
- Blood glucose instability
- Pulmonary oxygen effects
- Rare oxygen-induced seizure
An untreated pneumothorax is generally considered an absolute contraindication. Pulmonary air trapping, difficulty equalizing middle-ear pressure, unstable heart failure, seizure risk, implanted medical devices, and medication interactions require individualized assessment.
A history of prostate cancer is not itself a contraindication to HBOT. The treatment is directed at radiation-damaged tissue rather than the malignancy. Appropriate cancer surveillance should still continue before, during, and after the hyperbaric treatment course.
The Practical and Emotional Burden of Treatment
A full HBOT course may require daily attendance for six to eight weeks. Patients may also be managing urology appointments, PSA testing, catheter care, incontinence, anemia, cardiovascular disease, or other long-term effects of prostate cancer treatment.
Transportation, employment, caregiving responsibilities, urinary urgency, mobility limitations, and treatment fatigue should be discussed before the course begins.
The psychological burden of hematuria is also significant. Blood or clots in the urine can cause fear that prostate cancer has returned, even after testing supports radiation injury as the diagnosis. Recurrent bleeding may make patients reluctant to travel, exercise, participate in sexual activity, or spend time away from immediate restroom access.
Clinicians should explain clearly that HBOT is neither an instant method of stopping hemorrhage nor a guaranteed cure. It is a tissue-restorative treatment intended to improve the bladder’s vascular and healing environment over time.
For appropriately selected prostate cancer survivors, HBOT may reduce bleeding, improve urinary symptoms, limit repeated procedures, and support preservation of bladder function. The strongest care pathway combines hyperbaric treatment with continued urologic evaluation, prostate cancer surveillance, medication management, and prompt treatment of any acute bleeding complication.
